BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Targets Advanced Breast Cancer with Proprietary Immunotherapy
- Developing Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer
- Initiated FDA-approved phase IIa combination study of BRIA-IMT with Merck & Co. Inc.’s KEYTRUDA
- Impressive results in two proof-of-concept clinical trials reveal rapid response rate, repeated response following retreatment and excellent safety profile
Cancer immunotherapy market is anticipated to grow to $145 billion by 2022, at a CAGR of 14 percent
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage biotechnology company that’s currently focused on the development of targeted immunotherapy solutions for advanced breast cancer patients, has, to date, demonstrated excellent results with Bria-IMT in several clinical trials. BriaCell continues to concentrate on these cancer patients, who often enter the company’s clinical studies after thoroughly exhausting all other treatment options. This unmet medical need facing advanced breast cancer patients is real and growing ever more acute, as new cases of breast cancer are diagnosed daily. More than 2.1 million new cases were documented globally in 2018, according to the Cancer Research Institute (http://nnw.fm/Eh4zm).
BriaCell’s leading candidate, Bria-IMT, works by providing breast cancer antigens that directly stimulate T-cells to activate and boost their anti-cancer capabilities. Bria-IMT has already achieved proof of concept in clinical trials and is showing an outstanding safety profile, as well as excellent efficacy (http://nnw.fm/ReOu6). Currently, Bria-IMT’s effectiveness is being assessed in combination with KEYTRUDA (pembrolizumab) by Merck & Co., Inc. (NYSE: MRK). During the clinical trials, BriaCell’s cancer-fighting immunotherapy managed to elicit tumor regression even in the case of heavily pre-treated advanced breast cancer patients, as a recent article explains (http://nnw.fm/FUPr6).
“We believe that combination of Bria-IMT with immune checkpoint inhibitors should create even more potent anti-cancer immune responses,” BriaCell President and CEO Dr. Bill Williams stated in a recent news release (http://nnw.fm/11c4J). “BriaCell is committed to exploring additional ways to address the unmet needs of the advanced breast cancer community. We are very excited to test this novel combination treatment approach which we believe will offer significant clinical benefit to patients with advanced breast cancer.”
The imminent clinical use of a novel, frozen formulation of Bria-IMT is another exciting development for BriaCell. The company’s frozen formulation allows for the storage of cryopreserved, ready-to-inject Bria-IMT for cold-chain overnight transport to clinical sites, where it will be thawed prior to injection in patients. This unique formulation of Bria-IMT has also shown improved potency compared to the old formulation in vitro. Long term, this novel, frozen formulation is expected to carry reduced per-dose costs compared to the old formulation, as the company stated in a news release (http://nnw.fm/GS6f9). The frozen formulation will also be applicable to Bria-OTS, BriaCell’s personalized off-the-shelf immunotherapy, which is under development.
BriaCell recently announced the appointment of Jamieson Bondarenko to its board of directors. As an active investor, Bondarenko provides strategic capital markets and corporate development advice to early-stage life sciences companies through his merchant capital firm, JGRNT Capital Corp., according to a news release (http://nnw.fm/J8tSp).
“Jamieson brings extensive capital markets experience to BriaCell,” Dr. Saeid Babaei, BriaCell’s chairman of the board, stated in the release. “His expertise will be a valuable resource for BriaCell in the current investment environment as we execute our mission to bring innovative therapeutics to patients who tirelessly fight the deadliest forms of advanced breast cancer with no effective treatment options.”
Bondarenko was most recently principal, managing director, equity capital markets at Eight Capital. His previous roles include equity capital markets and investment banking positions at Dundee Capital Markets, Wellington West Capital Markets and HSBC Securities. He is a CFA charter holder and a chartered market technician.
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Developing Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer
- Initiated FDA-approved phase IIa combination study of BRIA-IMT with Merck & Co. Inc.’s KEYTRUDA
- Impressive results in two proof-of-concept clinical trials reveal rapid response rate, repeated response following retreatment and excellent safety profile
Cancer immunotherapy market is anticipated to grow to $145 billion by 2022, at a CAGR of 14 percent
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage biotechnology company that’s currently focused on the development of targeted immunotherapy solutions for advanced breast cancer patients, has, to date, demonstrated excellent results with Bria-IMT in several clinical trials. BriaCell continues to concentrate on these cancer patients, who often enter the company’s clinical studies after thoroughly exhausting all other treatment options. This unmet medical need facing advanced breast cancer patients is real and growing ever more acute, as new cases of breast cancer are diagnosed daily. More than 2.1 million new cases were documented globally in 2018, according to the Cancer Research Institute (http://nnw.fm/Eh4zm).
BriaCell’s leading candidate, Bria-IMT, works by providing breast cancer antigens that directly stimulate T-cells to activate and boost their anti-cancer capabilities. Bria-IMT has already achieved proof of concept in clinical trials and is showing an outstanding safety profile, as well as excellent efficacy (http://nnw.fm/ReOu6). Currently, Bria-IMT’s effectiveness is being assessed in combination with KEYTRUDA (pembrolizumab) by Merck & Co., Inc. (NYSE: MRK). During the clinical trials, BriaCell’s cancer-fighting immunotherapy managed to elicit tumor regression even in the case of heavily pre-treated advanced breast cancer patients, as a recent article explains (http://nnw.fm/FUPr6).
“We believe that combination of Bria-IMT with immune checkpoint inhibitors should create even more potent anti-cancer immune responses,” BriaCell President and CEO Dr. Bill Williams stated in a recent news release (http://nnw.fm/11c4J). “BriaCell is committed to exploring additional ways to address the unmet needs of the advanced breast cancer community. We are very excited to test this novel combination treatment approach which we believe will offer significant clinical benefit to patients with advanced breast cancer.”
The imminent clinical use of a novel, frozen formulation of Bria-IMT is another exciting development for BriaCell. The company’s frozen formulation allows for the storage of cryopreserved, ready-to-inject Bria-IMT for cold-chain overnight transport to clinical sites, where it will be thawed prior to injection in patients. This unique formulation of Bria-IMT has also shown improved potency compared to the old formulation in vitro. Long term, this novel, frozen formulation is expected to carry reduced per-dose costs compared to the old formulation, as the company stated in a news release (http://nnw.fm/GS6f9). The frozen formulation will also be applicable to Bria-OTS, BriaCell’s personalized off-the-shelf immunotherapy, which is under development.
BriaCell recently announced the appointment of Jamieson Bondarenko to its board of directors. As an active investor, Bondarenko provides strategic capital markets and corporate development advice to early-stage life sciences companies through his merchant capital firm, JGRNT Capital Corp., according to a news release (http://nnw.fm/J8tSp).
“Jamieson brings extensive capital markets experience to BriaCell,” Dr. Saeid Babaei, BriaCell’s chairman of the board, stated in the release. “His expertise will be a valuable resource for BriaCell in the current investment environment as we execute our mission to bring innovative therapeutics to patients who tirelessly fight the deadliest forms of advanced breast cancer with no effective treatment options.”
Bondarenko was most recently principal, managing director, equity capital markets at Eight Capital. His previous roles include equity capital markets and investment banking positions at Dundee Capital Markets, Wellington West Capital Markets and HSBC Securities. He is a CFA charter holder and a chartered market technician.
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
